.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Ranitidine hydrochloride - Generic Drug Details

« Back to Dashboard
Ranitidine hydrochloride is the generic ingredient in seven branded drugs marketed by Ranbaxy, Wockhardt, Apotex Inc, Bio Pharm Inc, Glaxo Grp Ltd, Pharm Assoc, Dr Reddys Labs Inc, Amneal Pharms, Strides Pharma, Watson Labs, Sandoz, Boehringer Ingelheim, Aurobindo Pharm, Mylan, Actavis Mid Atlantic, Amneal Pharms Ny, Watson Labs Inc, Perrigo R And D, Sun Pharm Inds Ltd, Zydus Pharms Usa Inc, Svads Holdings Sa, Dr Reddys Labs Ltd, Glenmark Generics, Tolmar, Teva, West-ward Pharms Int, Bedford, Ivax Sub Teva Pharms, Torpharm, Mylan Labs Ltd, Taro, Hi Tech Pharma, Apotex, Par Pharm, Breckenridge Pharm, Silarx, Igi Labs Inc, Vintage Pharms, Nostrum Labs Inc, Contract Pharmacal, Glaxosmithkline, and Perrigo, and is included in seventy NDAs. Additional information is available in the individual branded drug profile pages.

There are forty-two drug master file entries for ranitidine hydrochloride. One hundred and thirty-eight suppliers are listed for this compound.

Summary for Generic Name: ranitidine hydrochloride

Tradenames:7
Patents:0
Applicants:42
NDAs:70
Drug Master File Entries: see list42
Suppliers / Packaging: see list138
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: ranitidine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms
RANITIDINE HYDROCHLORIDE
ranitidine hydrochloride
SYRUP;ORAL078312-001Sep 2, 2008RXNo► subscribe► subscribe
Sandoz
RANITIDINE HYDROCHLORIDE
ranitidine hydrochloride
CAPSULE;ORAL074655-002Oct 22, 1997RXYes► subscribe► subscribe
Boehringer Ingelheim
ZANTAC 75
ranitidine hydrochloride
TABLET;ORAL020520-001Dec 19, 1995OTCNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ranitidine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd
ZANTAC 300
ranitidine hydrochloride
TABLET;ORAL018703-002Dec 9, 19854,521,431*PED► subscribe
Igi Labs Inc
ZANTAC IN PLASTIC CONTAINER
ranitidine hydrochloride
INJECTABLE;INJECTION019593-001Dec 17, 19864,521,431*PED► subscribe
Igi Labs Inc
ZANTAC
ranitidine hydrochloride
INJECTABLE;INJECTION019090-001Oct 19, 19844,521,431*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc